Literature DB >> 6459384

Studies on induction and effector functions of concanavalin A-induced suppressor cells that limit TCGF production.

M Gullberg, E L Larsson.   

Abstract

The cellular mechanisms regulating TCGF production in Con A-stimulated cultures have been investigated. Normal spleen cells, activated by Con A for 24 hr, develop suppressive cells that inhibit de novo production of TCGF by fresh spleen cells. Effector cells mediating suppression are nonadherent, radioresistant, Lyt-2-positive T cells. The induction of suppressor cells is radiosensitive and it requires 18 hr. The kinetics of suppressor cell induction parallels very closely the termination of TCGF production in situ, suggesting the major importance of this mechanism in the control of TCGF production. Reculture of 24-hr Con A-activated cells in the absence of Con A for 24 to 72 hr results in a gradual loss of suppressive activity that can be recalled by readdition of Con A with the same kinetics found in fresh spleen cells. In addition, de novo production of TCGF is readily induced in such cultures upon restimulation with Con A, demonstrating that abrogation of TCGF-production in primary cultures is due to suppression and not to lectin-dependent killing of the TCGF-producing T cells. Measurements of suppressive activity and lectin-dependent cytotoxicity, in various populations of Con A-activated spleen cells, further distinguish these activities. Finally, the reduced suppressive activity of Con A-activated cells after expansion in TCGF excludes that suppressor cells act by absorption or removal of TCGF produced at normal rates. Direct, reversible suppression of TCGF-producing cells by T lymphocytes appears, therefore, to constitute a major mechanism by which cytotoxic T cell responses are regulated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6459384

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Regulation of herpes simplex virus-specific lymphoproliferation by suppressor cells.

Authors:  D W Horohov; R N Moore; B T Rouse
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

2.  Regulation of lymphocyte proliferation in contact sensitivity: homeostatic mechanisms and a possible explanation of antigenic competition.

Authors:  I Kimber; C J Shepherd; J A Mitchell; J L Turk; D Baker
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

3.  Recombinant human interleukin-2 reverses in vitro-deficient cell-mediated immune responses to tuberculin purified protein derivative by lymphocytes of tuberculous patients.

Authors:  H Shiratsuchi; Y Okuda; I Tsuyuguchi
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

4.  Influence of dose and route of Mycobacterium lepraemurium inoculation on the production of interleukin 1 and interleukin 2 in C57BL/6 mice.

Authors:  A Hoffenbach; P H Lagrange; M A Bach
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

5.  Functional characterization of a regulatory human T-cell subpopulation increasing during autologous MLR.

Authors:  M E Cosulich; A Risso; G W Canonica; A Bargellesi
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

6.  Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma.

Authors:  L Grazioli; M Sensi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Characterization of lymphocytes that suppress IL-2 production in systemic lupus erythematosus.

Authors:  M Linker-Israeli; J D Gray; F P Quismorio; D A Horwitz
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

8.  Superinduction of the human gene encoding immune interferon.

Authors:  M A Lebendiker; C Tal; D Sayar; S Pilo; A Eilon; Y Banai; R Kaempfer
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

9.  Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2.

Authors:  N Nogueira; G Kaplan; E Levy; E N Sarno; P Kushner; A Granelli-Piperno; L Vieira; V Colomer Gould; W Levis; R Steinman
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.